FDA Approved Indications for this Orphan Drug:

Treatment of patients with metastatic, squamous, non-small cell lung cancer progressing after platinum-based chemotherapy

FDA Marketing Approval issued as of:

Orphan Drug exclusivity ends on:
Company Making and Marketing this drug:
Boehringer Ingelheim Pharmaceuticals, Inc.

FDA Designation Date:

FDA Drug Designation:
Treatment of non-small cell lung cancer with squamous histology.